Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mephenoxalone→

Mephenoxalone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
70-07-5
Molecular formula
C11H13NO4
Molecular weight
223.22 g/mol
Drug class
Centrally acting skeletal muscle relaxantoxazolidinone derivative
Mechanism of action
The precise mechanism is not fully characterised. Mephenoxalone produces central nervous system depression and reduces muscle hyperactivity and spasm; it is structurally related to older centrally acting muscle relaxants.
Indications / reported uses
  • Short-term symptomatic treatment of painful muscle spasm associated with musculoskeletal conditions in countries where mephenoxalone is authorised.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=mephenoxalone · https://www.ncbi.nlm.nih.gov/mesh/?term=mephenoxalone

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mephenoxalone Environmental Risk Assessment (ERA) (the Mephenoxalone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.